We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
University of Pittsburgh Selects GenomOncology
Product News

University of Pittsburgh Selects GenomOncology

University of Pittsburgh Selects GenomOncology
Product News

University of Pittsburgh Selects GenomOncology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "University of Pittsburgh Selects GenomOncology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GenomOncology has announced that the University of Pittsburgh has selected GenomOncology’s GenomAnalytics™ platform and services to explore and mine the breadth of data that exists in The Cancer Genome Atlas (TCGA).

Cancer is a complex disease of the genome with each tumor having its own set of genetic anomalies. Increased understanding of the genetic changes in cancer cells can lead to precise treatment strategies tailored to the genetic profile of each patient’s cancer.

To further this understanding and advance treatment options, the National Institutes of Health (NIH) has established The Cancer Genome Atlas (TCGA) Data Portal that allows researchers to access and analyze comprehensive, multi-dimensional maps of the key genomic changes in major types and subtypes of cancer.

To date, the TCGA project has focused on more than 20 cancer types and amassed thousands of samples. These samples will be further characterized to include single nucleotide variants, copy number variants, expression level changes, methylation and clinical phenotype data. The University of Pittsburg is one of the largest contributors to TCGA.

The GenomAnalytics platform will be used to investigate and visualize cancer genomic research data as a part of the University’s Personalized Medicine research initiative.

This project will engage the cancer research community and leverage the GenomAnlaytics platform to develop, validate and review scientific hypotheses associated with the unique drivers associated with cancer.

“GenomOncology is honored to work with the University of Pittsburgh on this important initiative.” said Manuel Glynias, President and CEO of GenomOncology. “We are confident that our robust technology platform and onsite support will accelerate the interpretation of the diverse amount of data in TCGA.”

Advertisement